Bioventus (NYSE:BVS) Director Sells $75,700.00 in Stock

Bioventus Inc. (NYSE:BVS - Get Free Report) Director Guy Nohra sold 10,000 shares of the business's stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $7.57, for a total transaction of $75,700.00. Following the sale, the director owned 116,610 shares of the company's stock, valued at approximately $882,737.70. This represents a 7.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.Bioventus Stock PerformanceShares of BVS traded up $0.10 during trading hours on Monday, hitting $7.19. The stock had a trading volume of 277,376 shares, compared to its average volume of 374,594. Bioventus Inc. has a 12 month low of $5.81 and a 12 month high of $11.85. The firm has a market capitalization of $595.07 million, a PE ratio of -11.79 and a beta of 0.79. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The stock has a fifty day moving average price of $7.08 and a 200 day moving average price of $6.93. Hedge Funds Weigh In On BioventusInstitutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. lifted its stake in shares of Bioventus by 23,761.5% during the 1st quarter. Russell Investments Group Ltd. now owns 6,204 shares of the company's stock worth $57,000 after acquiring an additional 6,178 shares during the last quarter. Covestor Ltd lifted its stake in shares of Bioventus by 28.0% during the 3rd quarter. Covestor Ltd now owns 9,951 shares of the company's stock worth $67,000 after purchasing an additional 2,176 shares during the last quarter. PharVision Advisers LLC purchased a new stake in shares of Bioventus during the 2nd quarter valued at $67,000. HB Wealth Management LLC purchased a new position in shares of Bioventus in the 3rd quarter valued at approximately $72,000. Finally, Fox Run Management L.L.C. acquired a new position in shares of Bioventus in the 2nd quarter valued at $72,000. 62.94% of the stock is owned by institutional investors. Bioventus Company Profile (Get Free Report)Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.Featured ArticlesFive stocks we like better than BioventusDo Real Estate Investment Trusts Deserve a Place in Your Portfolio?ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again3 Best Fintech Stocks for a Portfolio Boost5 Tech Stocks Insiders Are Selling (But Smart Investors Are Loading Up)What is a Microcap Stock? Everything You Need to Know Why FuelCell Energy Stock Is Soaring After a Government DealThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Bioventus Right Now?Before you consider Bioventus, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventus wasn't on the list.While Bioventus currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here